This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
No power calculations were reported. There was no sample selection; all patients meeting the inclusion criteria were included in the study sample. The patients in the control group were admitted to the Shikoku Cancer centre between October 2000 and December 2001, while those in the pathway group were admitted to the centre between January 2002 and March 2003. Initially, there were 24 patients in the clinical pathway group and 21 patients in the control group. One patient in each group had to be excluded from the study as it was discovered that they had rectal cancer. Thus, there were 20 patients in the control group and 23 patients in the pathway group. The mean age was 70.5 (+/-6.7) years (range: 48 -84) for the overall sample, 69.8 (+/-7.7) years in the control group and 71.1 (+/-5.6) years in the pathway group. The male-to-female ratio was 15:5 in the control group and 17:6 in the pathway group.
Study design
This was a single-centred, non-randomised study with historical controls. The patients were not followed up after hospital discharge. The follow-up period was reported to have been 18 months before and after January 2002. No loss to follow-up was reported.
Analysis of effectiveness
The analysis was conducted on an intention to treat basis. The primary health outcomes used were the size of the resected specimen, the proportion of patients who suffered bleeding, and the proportion who suffered from perforation. There was no statistically significant difference between the patient groups at baseline in terms of their demographics and the size of the lesion.
Effectiveness results
The size of the resected specimen was 30.9 (+/-9.0) mm in the control group and 28.7 (+/-7.8) mm in the clinical pathway group. The difference was not statistically significant.
The bleeding rate was 45% (n=9) in the control group and 56.5% (n=13) in the clinical pathway group. The difference was not statistically significant.
There were no cases of perforation.
Five patients in the pathway group did not follow the pathway and were discharged on postoperative day 8 or later, resulting in a variance rate of 21.7%. They started eating late as a result of bleeding.
Clinical conclusions
There were no statistically significant differences in the health outcomes between the patients treated before the pathway was introduced and those treated after its introduction.
